Aarti Drugs Ltd. Reports Audited Standalone and Consolidated Earnings Results for Second Quarter and Six Months Ended September 30, 2016
November 09, 2016 at 07:43 am EST
Share
Aarti Drugs Ltd. reported audited standalone and consolidated earnings results for second quarter and six months ended September 30, 2016. For the quarter, the company reported standalone net sales/income from operations of INR 2,866.6 million, profit from operations before other income and finance costs and exceptional items of INR 383.2 million, profit from ordinary activities before tax of INR 300.0 million, net profit of INR 201.0 million compared to the net sales/income from operations of INR 2,575.2 million, profit from operations before other income and finance costs and exceptional items of INR 331.7 million, profit from ordinary activities before tax of INR 225.1 million, net profit of INR 155.1 million for the same quarter a year ago. Earnings per share per basic and diluted were INR 8.30 compared to INR 6.41 for the same period a year ago.
For the year to date, the company reported standalone net sales/income from operations of INR 5,558.4 million, profit from operations before other income and finance costs and exceptional items of INR 729.3 million, profit from ordinary activities before tax of INR 551.4 million, net profit of INR 374.4 million compared to the net sales/income from operations of INR 5,208.2 million, profit from operations before other income and finance costs and exceptional items of INR 680.2 million, profit from ordinary activities before tax of INR 470.5 million, net profit of INR 325.6 million for the same period a year ago. Earnings per share per basic and diluted were INR 15.48 compared to INR 13.45 for the same period a year ago.
For the quarter, the company reported consolidated net sales/income from operations of INR 3,151.1 million, profit from operations before other income and finance costs and exceptional items of INR 414 million, profit from ordinary activities before tax of INR 326.2 million, net profit of INR 220.7 million compared to the net sales/income from operations of INR 2,726.4 million, profit from operations before other income and finance costs and exceptional items of INR 334.9 million, profit from ordinary activities before tax of INR 227.1 million, net profit of INR 157.1 million for the same quarter a year ago. Earnings per share per basic and diluted were INR 9.11 compared to INR 6.49 for the same period a year ago.
For the year to date, the company reported consolidated net sales/income from operations of INR 3,066.1 million, profit from operations before other income and finance costs and exceptional items of INR 799.1 million, profit from ordinary activities before tax of INR 611.7 million, net profit of INR 420.1 million compared to the net sales/income from operations of INR 5,559.2 million, profit from operations before other income and finance costs and exceptional items of INR 688.3 million, profit from ordinary activities before tax of INR 476.1 million, net profit of INR 331.1 million for the same period a year ago. Earnings per share per basic and diluted were INR 17.35 compared to INR 13.35 for the same period a year ago. Consolidated EBITDA is INR 511.4 million, up by 16.23%.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.